JZP258

DRUG2 trials

Sponsors

Jazz Pharmaceuticals PLC, Jazz Pharmaceuticals

Conditions

Narcolepsy

Phase 3

An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV

CompletedCTIS2023-504892-25-00

Jazz Pharmaceuticals PLCNarcolepsy

Start: 2024-06-14End: 2025-03-10Target: 37Updated: 2025-03-06

Phase 4

A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy

CompletedNCT05869773

Jazz PharmaceuticalsNarcolepsy

Start: 2023-06-26End: 2025-03-10Updated: 2026-04-24

Related Papers

Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.

2025-10-15

Abstract FR498: Impact of Switching From High- to Low-Sodium Oxybate on Ambulatory and Office Blood Pressure in Subgroups of People With Narcolepsy From the XYLO Study

Hypertension2025-09-01

0632 Design Elements for a Switch Study from High- to Low-Sodium Oxybate Evaluating Blood Pressure in Narcolepsy (XYLO)

SLEEP2024-04-20